ClinicalTrials.gg
CompletedNCT02183376Updated Jul 8, 2014

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

A Phase 1 interventional study of BI 1356 in Hepatic Insufficiency, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Hepatic Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Hepatic Insufficiency · Boehringer Ingelheim.

Enrollment
7th of 13
33 · median 33
Started
2008
the only one that year
Phase 1
12 of 13
none open now
Registered
4th of 13
by date

Among the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 12 in phase 1, and was the 4th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

None of the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim is open now. The open studies under Hepatic Insufficiency, anywhere →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim as a file.
02

Study summary

To investigate the influence of mild, moderate, and severe liver impairment on the pharmacokinetics and pharmacodynamics of linagliptin in comparison with a control group with normal hepatic function after single or multiple oral administration of 5 mg linagliptin tablets

03

Conditions studied

  • Hepatic Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Patients with hepatic impairment determined by results of screening classified as mild ( class A, score 6 points), moderate (Child-Pugh class B, score 7 to 9 points) or severe (Child-Pugh class C, score 10 to 15 points)
  • Healthy males and females based on a complete medical history, including physical examination, vital signs (BP, PR), 12-lead , and clinical laboratory tests
  • Subjects in the respective groups were matched with regard to age (±10 years), weight (±20%) and gender
  • Age 18 to 70 years, inclusive
  • 18.5 to 29.9 kg/m2, inclusive
  • ≥80 mL/min (except for patients with severe hepatic impairment, see exclusion criteria) according to Cockroft \& Gault
  • Signed and dated written prior to admission to the study in accordance with good clinical practice and local legislation

Exclusion Criteria:

Exclusion criteria for all subjects

  • Surgery of the gastrointestinal tract (except appendectomy and oesophageal varices)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders (except hepatoportal encephalopathy)
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections (except non-progressive chronic hepatitis not being in a progressive state)
  • History of relevant allergy or (including allergy to study drug or its )
  • Use of drugs which might reasonably influence the results of the trial or prolong the or QTc intervals (based on the knowledge at the time of preparing the Clinical Trial Protocol) within 10 days prior to study drug administration or during the trial
  • Participation in another trial with an drug within 2 months prior to study drug administration or during the trial
  • Smoking (more than 10 cigarettes, 3 cigars, or 3 pipes per day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (>100 mL within 4 weeks prior to study drug administration or during the trial)
  • Excessive physical activities (within 1 week prior to study drug administration or during the trial)
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT or QTc intervals (e.g. repeated demonstration of a QTc interval >450 ms)
  • A history of additional risk factors for torsade de pointes such as heart failure, severe hypokalemia (\<3.0 mmol/L), family history of long QT syndrome

Additional/modified exclusion criteria for healthy volunteers

  • Any finding of the medical examination (including BP, PR, and ECG) deviating from normal and of clinical relevance
  • Any evidence of a concomitant disease
  • Intake of drugs with a long half-life (>24 h) within 1 month or less than 10 half-lives of the respective drug prior to study drug administration or during the trial
  • Any laboratory value outside the reference range of clinical relevance

Additional/modified exclusion criteria for patients with hepatic impairment

  • Decompensated gastrointestinal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
  • Patients with severe liver impairment (Child-Pugh C): Severe concurrent renal dysfunction (e.g. due to hepatorenal syndrome) and a creatinine clearance \<40mL/min
  • Intake of drugs with a long half-life (>24 h) within 1 month or less than 10 half-lives of the respective drug prior to study drug administration or during the trial and intake of metformin; drugs taken for treatment of the underlying disease are excluded
  • Any laboratory value outside the reference range that is of clinical relevance, except for parameters related to liver impairment (e.g. albumin, , enzymes) and liver function tests according to Child-Pugh classification

Additional exclusion criteria for female subjects

  • Pregnancy or intention to become pregnant within 2 months of study completion
  • Positive pregnancy test
  • Lack of adequate (e.g. sterilisation, intrauterine device) or have not been using a barrier method of contraception for at least 3 months prior to the study
  • Unwillingness or inability to use a reliable method of barrier contraception (e.g. diaphragm with spermicidal cream or jelly or condoms with spermicidal foam), during the study and up to 2 months after completion or termination of the trial
  • Unwillingness of partner to use condoms
  • Lactation period
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    BI 1356 - healthy subjects

    Drug: BI 1356

  • Experimental
    BI 1356 - mild liver impairment

    Drug: BI 1356

  • Experimental
    BI 1356 - moderate liver impairment

    Drug: BI 1356

  • Experimental
    BI 1356 - severe liver impairment

    Drug: BI 1356

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24 h after the last dose at steady state) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  2. Cmax,ss (maximum concentration of the analyte in plasma at steady state) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  3. AUC0-24 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24 h after the first dose) for patients with severe liver impairment

    Time frame: up to 24 hours after drug administration

  4. Cmax (maximum concentration of the analyte in plasma) for patients with severe liver impairment

    Time frame: up to day 6

Secondary outcomes

  1. Plasma protein binding

    Time frame: up to day 12

  2. Model-derived AUCτ,ss for patients with severe liver impairment

    Time frame: up to day 6

  3. Model-derived Cmax,ss for patients with severe liver impairment

    Time frame: up to day 6

  4. Plasma dipeptidyl peptidase-4 (DPP-4) activity

    Time frame: up to day 6

  5. Plasma DPP-4 concentration

    Time frame: Day 1 (Baseline)

  6. Number of patients with adverse events

    Time frame: up to 47 days

  7. Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))

    Time frame: Baseline, up to day 19

  8. Number of patients with clinically relevant findings in 12-lead electrocardiogram (ECG)

    Time frame: Baseline, up to day 19

  9. Number of patients with clinically relevant findings in clinical laboratory tests

    Time frame: Baseline, up to day 19

  10. Assessment of tolerability by investigator on a 4-point scale

    Time frame: day 19

  11. tmax(ss) (time from last dose to maximum concentration of the analyte in plasma after single dose/at steady state) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  12. C24(ss) (concentration of the analyte in plasma at steady state after administration of the first or last dose at the end of the dosing interval) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  13. λz(ss) (terminal rate constant in plasma after single dose/at steady state) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  14. t1/2(ss) (terminal half-life of the analyte in plasma after single dose/at steady state) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  15. MRTpo(ss) (mean residence time of the analyte in the body after oral administration after single dose/at steady state) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  16. CL/F(ss) (apparent clearance of the analyte in the plasma after extravascular administration after single dose/at steady state) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  17. Vz/F(ss) (apparent volume of distribution during the terminal phase λz following extravascular administration after single dose/at steady state) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  18. AUC0-24 (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to 24 h after the first dose for multiple dose groups) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to 24 hours after the first dose

  19. Cmax (maximum concentration of the analyte in plasma after the first dose in multiple dose groups) for healthy patients and patients with mild and moderate liver impairment

    Time frame: up to day 12

  20. %AUCtz-∞ (percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity after single dose) in patients with severe liver impairment

    Time frame: up to day 6

  21. AUC0-∞ (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose in patients with severe liver impairment)

    Time frame: up to day 6

  22. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point after single dose in patients with severe liver impairment)

    Time frame: up to day 6

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008 and a primary completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Jul 2008
Primary completionActual
Mar 2009
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183376
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jul 2008
Primary completion
Mar 2009
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion